Foley Hoag1 min read
Could new US investment curbs complicate China’s biotech licensing surge?
Chinese biotech firms face fresh headwinds in their global expansion as Washington’s proposed outbound investment restrictions threaten to disrupt deal structures, even though drug licensing agreements remain untouched for now, analysts say.
By Xinmei ShenSouth China Morning Post Tech

Read the full story
Originally published by South China Morning Post Tech on Oct 26, 2026.
Comments
Sign in to join the discussion.